Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 4691389, 7 pages
https://doi.org/10.1155/2017/4691389
Research Article

Urinary Neutrophil Gelatinase-Associated Lipocalin Is Complementary to Albuminuria in Diagnosis of Early-Stage Diabetic Kidney Disease in Type 2 Diabetes

1Department of Dialysis and Nephrology, St. Queen Jadwiga Clinical District Hospital No. 2 in Rzeszów, Lwowska 60 Street, 35-301 Rzeszów, Poland
2Department of Medical Diagnostics, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
3Department of Diagnostics, Chair of Clinical Biochemistry, Jagiellonian University Medical College, 15A Kopernika Street, 31-501 Krakow, Poland
4Department of Internal Medicine, Nephrology & Endocrinology, St. Queen Jadwiga Clinical District Hospital No. 2 in Rzeszów, Lwowska 60 Street, 35-301 Rzeszów, Poland
5St. Queen Jadwiga Clinical District Hospital No. 2 in Rzeszów, Lwowska 60 Street, 35-301 Rzeszów, Poland
6Department of Nephrology, Jagiellonian University Medical College, 15 Kopernika Street, 31-501 Krakow, Poland

Correspondence should be addressed to Agnieszka Gala-Błądzińska; lp.pw@ycsnizdalb

Received 4 January 2017; Revised 19 March 2017; Accepted 6 July 2017; Published 6 August 2017

Academic Editor: Richard Coward

Copyright © 2017 Agnieszka Gala-Błądzińska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. da Rocha Fernandes, K. Ogurtsova, U. Linnenkamp et al., “IDF Diabetes Atlas estimates of 2014 global health expenditures on diabetes,” Diabetes Research and Clinical Practice, vol. 117, pp. 48–54, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Roglic, Ch. Varghese, L. Riley, and et al., Global Report on Diabetes, World Health Organization, Geneva, 2016, http://www.who.int/.
  3. S. L. White, S. J. Chadban, S. Jan, J. R. Chapman, and A. Cass, “How can we achieve global equity in provision of renal replacement therapy?” Bulletin of the World Health Organization, vol. 86, no. 3, pp. 229–237, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Trevisan, D. J. Barues, and G. C. Viberti, “Pathogenesis of diabetic nephropathy,” in Textbook of Diabetes, J. C. Pickup and G. Wiliams, Eds., pp. 52.1-53.1, Blackwell Science Ltd., Oxford, UK, 2nd edition, 1997. View at Publisher · View at Google Scholar
  5. E. Espinel, I. Agraz, M. Ibernon, N. Ramos, J. Fort, and D. Serón, “Renal biopsy in type 2 diabetic patients,” Journal of Clinical Medicine, vol. 4, no. 5, pp. 998–1009, 2015. View at Publisher · View at Google Scholar
  6. P. Fioretto, M. Mauer, E. Brocco et al., “Patterns of renal injury in NIDDM patients with microalbuminuria,” Diabetologia, vol. 39, no. 12, pp. 1569–1576, 1996. View at Publisher · View at Google Scholar · View at Scopus
  7. M. M. Schwartz, E. J. Lewis, T. Leonard-Martin et al., “Renal pathology patterns in type II diabetes mellitus: relationship with retinopathy,” Nephrology Dialysis Transplantation, vol. 13, no. 10, pp. 2547–2552, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. D. R. Flower, “Experimentally determined lipocalin structures,” Biochimica et Biophysica Acta—Protein Structure and Molecular Enzymology, vol. 1482, no. 1-2, pp. 46–56, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Mishra, M. A. Qing, A. Prada et al., “Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury,” Journal of the American Society of Nephrology, vol. 14, no. 10, pp. 2534–2543, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Haase, R. Bellomo, and A. Haase-Fielitz, “Neutrophil gelatinase-associated lipocalin,” Current Opinion in Critical Care, vol. 16, no. 6, pp. 526–532, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. K.-M. Chou, C.-C. Lee, C.-H. Chen, and C.-Y. Sun, “Clinical value of NGAL, L-FABP and albuminuria in predicting GFR decline in type 2 diabetes mellitus patients,” PLoS ONE, vol. 8, no. 1, article e54863, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. S. E. Nielsen, S. Andersen, D. Zdunek, G. Hess, H.-H. Parving, and P. Rossing, “Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy,” Kidney International, vol. 79, no. 10, pp. 1113–1118, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. S. E. Nielsen, K. J. Schjoedt, and A. S. Astrup, “Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril,” Diabetic Medicine, vol. 27, no. 10, pp. 1144–1150, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. W. Fu, S. Xiong, Y. Fang et al., “Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study,” Endocrine, vol. 41, no. 1, pp. 82–88, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. S. S. Kim, S. H. Song, I. J. Kim et al., “Nonalbuminuric proteinuria as a biomarker for tubular damage in early development of nephropathy with type 2 diabetic patients,” Diabetes/Metabolism Research and Reviews, vol. 30, no. 8, pp. 736–741, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Wu, Y. Ding, C. Zhu et al., “Urinary TNF-α and NGAL are correlated with the progression of nephropathy in patients with type 2 diabetes,” Experimental and Therapeutic Medicine, vol. 6, no. 6, pp. 1482–1488, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. M.-A. Gall, P. Rossing, P. Skøtt et al., “Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European Type 2 (non-insulin-dependent) diabetic patients,” Diabetologia, vol. 34, no. 9, pp. 655–661, 1991. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Prakash, T. Gupta, S. Prakash et al., “Non-diabetic renal disease in type 2 diabetes mellitus: study of renal—retinal relationship,” Indian Journal of Nephrology, vol. 25, no. 4, pp. 222–228, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Soleymanian, G. Hamid, M. Arefi et al., “Non-diabetic renal disease with or without diabetic nephropathy in type 2 diabetes: clinical predictors and outcome,” Renal Failure, vol. 37, no. 4, pp. 572–575, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. M. A. Tonelli and C. Wanner, “Kidney disease: improving global outcomes (KDIGO) lipid work group. KDIGO clinical practice guideline for lipid management in chronic kidney disease,” Kidney International Supplements, vol. 3, no. 3, pp. 1–315, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Retnakaran, C. A. Cull, K. I. Thorne, A. I. Adler, and UKPDS Study Group, “Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective diabetes study 74,” Diabetes, vol. 55, pp. 1832–1839, 2006. View at Publisher · View at Google Scholar
  22. H.-H. Parving, J. B. Lewis, M. Ravid, G. Remuzzi, and L. G. Hunsicker, “Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective,” Kidney International, vol. 69, no. 11, pp. 2057–2063, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. K. M. Thrailkill, C. S. Moreau, G. E. Cockrell et al., “Disease and gender-specific dysregulation of NGAL and MMP-9 in type 1 diabetes mellitus,” Endocrine, vol. 37, no. 2, pp. 336–343, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. D.-H. Kang, E. S. Yu, K.-I. Yoon, and R. Johnson, “The impact of gender on progression of renal disease: potential role of estrogen-mediated vascular endothelial growth factor regulation and vascular protection,” American Journal of Pathology, vol. 164, no. 2, pp. 679–688, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Silbiger and J. Neugarten, “Gender and human chronic renal disease,” Gender Medicine, vol. 5, supplement 1, pp. S3–S10, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. S. R. Silbiger and J. Neugarten, “The role of gender in the progression of renal disease,” Advances in Renal Replacement Therapy, vol. 10, no. 1, pp. 3–14, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. A. K. Kang and J. A. Miller, “Impact of gender on renal disease: the role of the renin angiotensin system,” Clinical & Investigative Medicine, vol. 26, pp. 38–44, 2003. View at Google Scholar
  28. M. K. Yu, C. R. Lyles, L. A. Bent-Shaw, and B. A. Young, “Risk factor, age and sex differences in chronic kidney disease prevalence in a diabetic cohort: the pathways study and the pathways authors,” American Journal of Nephrology, vol. 36, no. 3, pp. 245–251, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. D. Z. I. Cherney, E. B. Sochett, and J. A. Miller, “Gender differences in renal responses to hyperglycemia and angiotensin-converting enzyme inhibition in diabetes,” Kidney International, vol. 68, no. 4, pp. 1722–1728, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. S. E. Nielsen, K. Rossing, G. Hess et al., “The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: U-NGAL, u-KIM1 and u-LFABP,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 72, no. 2, pp. 137–142, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. N. J. Brunskill, “Albumin and proximal tubular cells—beyond endocytosis,” Nephrology Dialysis Transplantation, vol. 15, no. 11, pp. 1732–1734, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. D. B. Johnstone and L. B. Holzman, “Clinical impact of research on the podocyte slit diaphragm,” Nature Clinical Practice Nephrology, vol. 2, no. 5, pp. 271–282, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. K. Zandi-Nejad, A. A. Eddy, R. J. Glassock, and B. M. Brenner, “Why is proteinuria an ominous biomarker of progressive kidney disease?” Kidney International, vol. 66, no. 92, pp. S76–S89, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. KDOQI, “KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease,” American Journal of Kidney Diseases, vol. 49, supplement 2, no. 2, pp. S12–S154, 2007. View at Publisher · View at Google Scholar
  35. H. Pavenstädt, W. Kriz, and M. Kretzler, “Cell biology of the glomerular podocyte,” Physiological Reviews, vol. 83, no. 1, pp. 253–307, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. F. B. Hickey and F. Martin, “Diabetic kidney disease and immune modulation,” Current Opinion in Pharmacology, vol. 13, no. 4, pp. 602–612, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Lin, W. H. Yiu, H. J. Wu et al., “Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 23, no. 1, pp. 86–102, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. S. D. Ricardo, H. van Goor, and A. A. Eddy, “Macrophage diversity in renal injury and repair,” Journal of Clinical Investigation, vol. 118, no. 11, pp. 3522–3530, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. V. Perkovic, H. L. Heerspink, J. Chalmers et al., “Intensive glucose control improves kidney outcomes in patients with type 2 diabetes,” Kidney International, vol. 83, no. 3, pp. 517–523, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. G. Tonolo, M. G. Melis, M. Formato et al., “Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients,” European Journal of Clinical Investigation, vol. 30, no. 11, pp. 980–987, 2000. View at Publisher · View at Google Scholar · View at Scopus
  41. T. Nagai, T. Tomizawa, K. Nakajima, and M. Mori, “Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients,” Journal of Atherosclerosis and Thrombosis, vol. 7, no. 2, pp. 91–96, 2000. View at Publisher · View at Google Scholar · View at Scopus